Editor's note: This article has been updated with a comment from a Pharmsource spokesperson. Continuous glucose monitoring specialist Dexcom has identified two lots of Dexcom G7 sensors (1725204004 ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were stolen by a third party before destruction and sold into the market. Dexcom is working closely with ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 ...
Add Yahoo as a preferred source to see more of our stories on Google. New data from Dexcom has demonstrated the benefit of its G7 continuous glucose monitor (CGM) in type 2 diabetes (TD2) patients not ...
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results